Paris and Boston, November 19, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that its Board of Directors, under the leadership of Chairman and CEO Sacha Loiseau, has authorized the management team to initiate a review of strategic alternatives for the Company.
The objective of this process is to evaluate a broad range of options to maximize shareholder value, ensure operational stability, and secure the necessary capital to unlock Cellvizio’s long-term commercial potential. Additionally, the Company aims to safeguard its broad intellectual property portfolio and optimize its valuation to the fullest extent.
The Company has retained Bucephale Finance as financial advisor to assist in its review of strategic alternatives.
Mauna Kea’s management will regularly update its shareholders and strategic partners on its progress.
